DB
BLRX

Danske Bank’s BioLineRX BLRX Stock Holding History

Danske Bank’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5 Hold
2
– – ﹤0.01% 1101
2025
Q4 		$6 Hold
2
– – ﹤0.01% 1494
2025
Q3 		$8 Hold
2
– – ﹤0.01% 1422
2025
Q2 		$9 Hold
2
– – ﹤0.01% 1466
2025
Q1 		$6 Buy
+2
New +$8 ﹤0.01% 1327

Other funds holding BLRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Danske Bank's BLRX Position: Q1 2026 in Review

Danske Bank held its BioLineRX (BLRX) position steady in Q1 2026 at 2 shares worth $5. The position accounts for ﹤0.01% of the portfolio, ranked #1101.

Danske Bank first reported a position in BLRX in Q1 2025 and has held it in 5 quarters since. The position peaked at $9 in Q2 2025. 13 funds tracked by Wall St. Rank hold BLRX as of Q1 2026.

  • Danske Bank held 2 shares of BioLineRX worth $5 as of Q1 2026.
  • Danske Bank left its BioLineRX share count unchanged in Q1 2026.
  • BioLineRX made up ﹤0.01% of Danske Bank's portfolio in Q1 2026, its #1101 holding.
  • Danske Bank first reported a position in BioLineRX in Q1 2025 and has held it in 5 quarters since.
  • Danske Bank's BioLineRX position peaked at $9 in Q2 2025.
  • 13 funds tracked by Wall St. Rank held BioLineRX as of Q1 2026.

Based on Danske Bank's 13F filing for Q1 2026, filed 12 May 2026.